Literature DB >> 18785269

Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.

Susan M Young1, Cristian M Bologa, Dan Fara, Bj K Bryant, Juan Jacob Strouse, Jeffrey B Arterburn, Richard D Ye, Tudor I Oprea, Eric R Prossnitz, Larry A Sklar, Bruce S Edwards.   

Abstract

Of recent, clinical interest have been two related human G-protein coupled receptors: formylpeptide receptor (FPR), linked to antibacterial inflammation and malignant glioma cell metastasis; and FPR like-1 (FPRL1), linked to chronic inflammation in systemic amyloidosis, Alzheimer's disease, and prion diseases. In association with the National Institutes of Health (NIH) Molecular Library Screening Network, we implemented a flow-cytometry-based high-throughput screening (HTS) approach for identifying selective small molecule FPR and FPRL1 ligands. The screening assay measured the ability of test compounds to competitively displace a high-affinity, fluorescein- labeled peptide ligand from FPR, FPRL1, or both. U937 cells expressing FPR and rat basophil leukemia (RBL) cells expressing FPRL1 were tested together in a "duplex" format. The U937 cells were color coded with red-fluorescent dye allowing their distinction during analysis. Compounds, cells, and fluorescent ligand were sequentially combined (no wash) in 15 microl assay volumes in 384-well plates. Throughput averaged approximately 11 min per plate to analyze approximately 4,000 cells ( approximately 2,000/receptor) in a 2 microl aspirate from each well. In primary single concentration HTS of 24,304 NIH Small Molecule Repository compounds, 253 resulted in inhibition >30% (181 for FPR, 72 for FPRL1) of which 40 had selective binding inhibition constants (K(i)) < or = 4 microM (34 for FPR and 6 for FPRL1). An additional 1,446 candidate compounds were selected by structure-activity-relationship analysis of the hits and screened to identify novel ligands for FPR (3570-0208, K(i) = 95 +/- 10 nM) and FPRL1 (BB-V-115, K(i) = 270 +/- 51 nM). Each was a selective antagonist in calcium response assays and the most potent small molecule antagonist reported for its respective receptor to date. The duplex assay format reduced assay time, minimized reagent requirements, and provided selectivity information at every screening stage, thus proving to be an efficient means to screen for selective receptor ligand probes. 2008 International Society for Advancement of Cytometry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18785269      PMCID: PMC2645486          DOI: 10.1002/cyto.a.20645

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  53 in total

1.  Expression of functional formyl peptide receptors by human astrocytoma cell lines.

Authors:  Y Le; J Hu; W Gong; W Shen; B Li; N M Dunlop; D O Halverson; D G Blair; J M Wang
Journal:  J Neuroimmunol       Date:  2000-11-01       Impact factor: 3.478

2.  A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR.

Authors:  A Walther; K Riehemann; V Gerke
Journal:  Mol Cell       Date:  2000-05       Impact factor: 17.970

3.  High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2007-01-17       Impact factor: 4.436

4.  Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.

Authors:  Roland W Bürli; Han Xu; Xiaoming Zou; Kristine Muller; Jennifer Golden; Mike Frohn; Matthew Adlam; Matthew H Plant; Min Wong; Michele McElvain; Kelly Regal; Vellarkad N Viswanadhan; Philip Tagari; Randall Hungate
Journal:  Bioorg Med Chem Lett       Date:  2006-05-11       Impact factor: 2.823

5.  N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.

Authors:  Y Le; S Jiang; J Hu; W Gong; S Su; N M Dunlop; W Shen; B Li; J Ming Wang
Journal:  Clin Immunol       Date:  2000-09       Impact factor: 3.969

6.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

7.  Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR.

Authors:  Xiao-Hong Yao; Yi-Fang Ping; Jian-Hong Chen; Dai-Lun Chen; Cheng-Ping Xu; Jiang Zheng; Ji Ming Wang; Xiu-Wu Bian
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

8.  Formyl peptide receptor-like 1 mediated endogenous TRAIL gene expression with tumoricidal activity.

Authors:  Chentao Lin; Wei Wei; Jinchun Zhang; Shilian Liu; Yanxin Liu; Dexian Zheng
Journal:  Mol Cancer Ther       Date:  2007-10       Impact factor: 6.261

9.  LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells.

Authors:  Q Chen; A P Schmidt; G M Anderson; J M Wang; J Wooters; J J Oppenheim; O Chertov
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.

Authors:  N Chiang; I M Fierro; K Gronert; C N Serhan
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  15 in total

1.  Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Authors:  Clemencia Pinilla; Bruce S Edwards; Jon R Appel; Tina Yates-Gibbins; Marc A Giulianotti; Jose L Medina-Franco; Susan M Young; Radleigh G Santos; Larry A Sklar; Richard A Houghten
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

2.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

3.  4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Authors:  Liliya N Kirpotina; Igor A Schepetkin; Andrei I Khlebnikov; Olga I Ruban; Yunjun Ge; Richard D Ye; Douglas J Kominsky; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2017-07-08       Impact factor: 5.858

Review 4.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Cluster cytometry for high-capacity bioanalysis.

Authors:  Bruce S Edwards; Jingshu Zhu; Jun Chen; Mark B Carter; David M Thal; John J G Tesmer; Steven W Graves; Larry A Sklar
Journal:  Cytometry A       Date:  2012-03-21       Impact factor: 4.355

Review 6.  Spectral flow cytometry.

Authors:  John P Nolan; Danilo Condello
Journal:  Curr Protoc Cytom       Date:  2013-01

7.  Discovery of regulators of receptor internalization with high-throughput flow cytometry.

Authors:  Yang Wu; Phillip H Tapia; Gregory W Fisher; Peter C Simons; J Jacob Strouse; Terry Foutz; Alan S Waggoner; Jonathan Jarvik; Larry A Sklar
Journal:  Mol Pharmacol       Date:  2012-07-05       Impact factor: 4.436

Review 8.  Flow Cytometry: Impact on Early Drug Discovery.

Authors:  Bruce S Edwards; Larry A Sklar
Journal:  J Biomol Screen       Date:  2015-03-24

Review 9.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

10.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.